Approval · Notice of Compliance 17830 · 2016
TARGIN: Notice of Compliance 17830
Issued March 3, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17830
- Date
- March 3, 2016
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a summary of in vitro laboratory drug abuse studies in action and clinical pharmacology of the product monograph as well as safety update related to dosing recommendations in hepatically or renally impaired patients
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TARGIN | Not yet assigned | — |
Medicinal ingredients
- NALOXONE HYDROCHLORIDE 2.5 MG per TAB
- OXYCODONE HYDROCHLORIDE 5 MG per TAB
- NALOXONE HYDROCHLORIDE 5 MG per TAB
- OXYCODONE HYDROCHLORIDE 10 MG per TAB
- NALOXONE HYDROCHLORIDE 10 MG per TAB
- OXYCODONE HYDROCHLORIDE 20 MG per TAB
- NALOXONE HYDROCHLORIDE 20 MG per TAB
- OXYCODONE HYDROCHLORIDE 40 MG per TAB